The IDeate-Lung01 trial showed a 48% confirmed response rate with Merck’s B7-H3 directed antibody-drug conjugate in previously treated extensive-stage small cell lung cancer, with durable benefit ...

Interim results from the ongoing Phase IV LOTUS trial showed that Daybue delivered sustained behavioral improvements and manageable gastrointestinal outcomes in Rett syndrome patients over one year.

In this week’s Applied Clinical Trials Brief, we recap three top stories: Novo Nordisk’s stepwise approach to AI adoption, ...

Results from the Phase III STRIDE-13 trial (NCT06177912) showed that Merck’s Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) demonstrated robust immune responses in children and adolescents aged ...

In this video interview, Umesh Chaudhari, executive medical director and global program head of the C5 programs at Regeneron, ...